CN102309561A - Pharmaceutical composition used for preventing and treating urarthritis and hyperuricemia - Google Patents
Pharmaceutical composition used for preventing and treating urarthritis and hyperuricemia Download PDFInfo
- Publication number
- CN102309561A CN102309561A CN 201010214332 CN201010214332A CN102309561A CN 102309561 A CN102309561 A CN 102309561A CN 201010214332 CN201010214332 CN 201010214332 CN 201010214332 A CN201010214332 A CN 201010214332A CN 102309561 A CN102309561 A CN 102309561A
- Authority
- CN
- China
- Prior art keywords
- pharmaceutical composition
- hyperuricemia
- prevent
- gouty arthritis
- treat
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 36
- 201000001431 Hyperuricemia Diseases 0.000 title claims abstract description 34
- 201000005569 Gout Diseases 0.000 claims abstract description 48
- 241000903946 Clematidis Species 0.000 claims abstract description 21
- 206010018634 Gouty Arthritis Diseases 0.000 claims description 30
- 239000002775 capsule Substances 0.000 claims description 5
- 239000002552 dosage form Substances 0.000 claims description 5
- 239000007788 liquid Substances 0.000 claims description 5
- 238000002360 preparation method Methods 0.000 claims description 5
- 239000008187 granular material Substances 0.000 claims description 4
- 239000006187 pill Substances 0.000 claims description 3
- 239000007901 soft capsule Substances 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 18
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 abstract description 14
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 abstract description 12
- 239000008280 blood Substances 0.000 abstract description 12
- 229940116269 uric acid Drugs 0.000 abstract description 12
- 210000004369 blood Anatomy 0.000 abstract description 11
- 208000002193 Pain Diseases 0.000 abstract description 7
- 230000036407 pain Effects 0.000 abstract description 7
- 230000007102 metabolic function Effects 0.000 abstract description 3
- 230000000630 rising effect Effects 0.000 abstract description 2
- 241001237097 Dianthus hyssopifolius Species 0.000 abstract 1
- 235000013535 Dianthus superbus Nutrition 0.000 abstract 1
- 241001071795 Gentiana Species 0.000 abstract 1
- 231100000331 toxic Toxicity 0.000 abstract 1
- 230000002588 toxic effect Effects 0.000 abstract 1
- 238000011282 treatment Methods 0.000 description 24
- 239000003814 drug Substances 0.000 description 12
- 201000010099 disease Diseases 0.000 description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 9
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- 230000003203 everyday effect Effects 0.000 description 5
- 229940079593 drug Drugs 0.000 description 4
- 235000013305 food Nutrition 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 208000006820 Arthralgia Diseases 0.000 description 3
- 241000283707 Capra Species 0.000 description 3
- 230000000202 analgesic effect Effects 0.000 description 3
- 235000005911 diet Nutrition 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 206010025482 malaise Diseases 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 239000002994 raw material Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 208000004880 Polyuria Diseases 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 206010003246 arthritis Diseases 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 230000035619 diuresis Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 208000006750 hematuria Diseases 0.000 description 2
- 230000003907 kidney function Effects 0.000 description 2
- 230000003908 liver function Effects 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 230000001617 migratory effect Effects 0.000 description 2
- 231100000957 no side effect Toxicity 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 201000004624 Dermatitis Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 1
- 208000026816 acute arthritis Diseases 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000036592 analgesia Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 239000003637 basic solution Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 230000000916 dilatatory effect Effects 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 230000001882 diuretic effect Effects 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 235000006694 eating habits Nutrition 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 230000007160 gastrointestinal dysfunction Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 238000009499 grossing Methods 0.000 description 1
- 208000035474 group of disease Diseases 0.000 description 1
- 230000004217 heart function Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000007954 hypoxia Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- NAFSTSRULRIERK-UHFFFAOYSA-M monosodium urate Chemical compound [Na+].N1C([O-])=NC(=O)C2=C1NC(=O)N2 NAFSTSRULRIERK-UHFFFAOYSA-M 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 238000003672 processing method Methods 0.000 description 1
- 230000004144 purine metabolism Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 230000008093 supporting effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 208000037816 tissue injury Diseases 0.000 description 1
- 230000003424 uricosuric effect Effects 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention relates to a pharmaceutical composition used for preventing and treating urarthritis and hyperuricemia. The pharmaceutical composition comprises the following components in parts by weight: 7-15 parts of fringed pink, 5-10 parts of radix clematidis and 5-13 parts of large-leaved gentian. The invention provides the pharmaceutical composition used for preventing and treating urarthritis and hyperuricemia, and the pharmaceutical composition can lower blood uric acid content of gout patients, alleviate pain, prevent uric acid from rising and restore and improve the metabolism function of the patients and has no toxic and side effects.
Description
Technical field
The invention belongs to field of medicaments, relate to a kind of pharmaceutical composition that is used to prevent and treat gouty arthritis and hyperuricemia.
Background technology
Gout is long-term purine metabolism obstacle, and blood uric acid raises and causes one group of disease of tissue injury.Clinical characters is: hyperuricemia, acute arthritis are shown effect repeatedly, tophus formation, chronic arthritis and joint deformity, and urate calculus and gouty parenchymal lesion of the kidney occur in the course of disease later stage.
The cause of gout: all contain not commensurability purine in all foods, different food units purine content even differ thousand times.After the for a long time edible high purine food of people, cause metabolism not smooth easily, it is too much that uricopoiesis takes place, and urate excretion occurs and reduce even acatharsia, causes uric acid rising in the blood, and the hematuria acid number exceeds 420 and gout just often occurs.
Gout is time-honored disease, B.C. 5th century medical science father Xi Bo carat at the bottom of just relevant for the record of gout clinical manifestation.Developed into Hesperian a kind of commonly encountered diseases afterwards.1684, the Anthony Leeuwenhoek was at first described the crystalline microscope outward appearance of uric acid sodium in the tophus.After this pass through countless scientists' effort, just this disease has been had than more comprehensively has been familiar with to the sixties in 19th century.
The traditional Chinese medical science can be traced back to " interior warp " to the understanding of gout, and " Medical Treasures of the Golden Chamber " further to being decided to be severe and migratory arthralgia with gout, and patient's sign, body constitution are described, and sends out well in fat it like gout and " contains people "; Gold dollar period, Zhu Danxi claims at " danxi's experiential therapy ": " gout person, extremity hundred joints are walked pain, the severe and migratory arthralgia of other party meaning." the famous Zhang Lu of doctor family of the Qing Dynasty says in his " Zhang Shi doctor logical ": " fertile people's podomere disease ... The dry parent of prime of life human nature has a liking for rich and fatty diet " these all are people to the understanding of gout valuable reference is provided.
Gout is a kind of commonly encountered diseases in European and American countries.Think that in the past it is more rare that gout person suffers from Asian Peoples, but sickness rate rises rapidly in recent decades.China reports only tens of examples of goat patient in the early days of foundation, in recent years, the raising of Along with people's living standard, the unscientific dietary structure of China, dietary habit in addition, people take in purine-containing food and increase, and the sickness rate of gout increases year by year.
Goat is high with its sickness rate, cures difficulty, and more the multiple anti-rate in back is high, produces with multiple complication, is classified as famous difficult miscellaneous diseases.The common therapeutic effect of goat is unsatisfactory.Western medicine medication at present generally can be divided three classes by the effect characteristics: the one, and gout outbreak medicine; The 2nd, uricosuric drug; The 3rd, uric acid synthesizes blocker.Though these three types of Western medicine can temporarily be obtained positive effect, side effect is big usually, is common in gastrointestinal dysfunction, and hepatic and renal function is impaired, erythra, dermatitis etc., and especially after the drug withdrawal, easy relapse is not so be basic solution.
Summary of the invention
In order to solve the above-mentioned technical problem that exists in the background technology, the invention provides and a kind ofly can reduce the pharmaceutical composition that is used to prevent and treat gouty arthritis and hyperuricemia that patient with gout blood uric acid content, alleviating pain, inhibition uric acid increase, recover and improve patient's metabolic function and has no side effect.
Technical solution of the present invention is: the invention provides a kind of pharmaceutical composition that is used to prevent and treat gouty arthritis and hyperuricemia, its special character is: the pharmaceutical composition that is used to prevent and treat gouty arthritis and hyperuricemia comprises the Herba Dianthi of 7-15 part, the Radix Clematidis of 5-10 part and the Radix Gentianae Macrophyllae of 5-13 part.
The above-mentioned pharmaceutical composition that is used to prevent and treat gouty arthritis and hyperuricemia comprises the Herba Dianthi of 8-13 part, the Radix Clematidis of 7-10 part and the Radix Gentianae Macrophyllae of 6-12 part.
The above-mentioned pharmaceutical composition that is used to prevent and treat gouty arthritis and hyperuricemia comprises the Herba Dianthi of 7-15 part, the Radix Clematidis of 5-10 part, the Radix Gentianae Macrophyllae of 5-13 part and the Ramulus Cinnamomi of 3-10 part.
The above-mentioned pharmaceutical composition that is used to prevent and treat gouty arthritis and hyperuricemia comprises the Herba Dianthi of 8-13 part, the Radix Clematidis of 7-10 part, the Radix Gentianae Macrophyllae of 6-12 part and the Ramulus Cinnamomi of 6-10 part.
The above-mentioned pharmaceutical composition that is used to prevent and treat gouty arthritis and hyperuricemia comprises the Herba Dianthi of 7-15 part, the Radix Clematidis of 5-10 part, the Radix Gentianae Macrophyllae of 5-13 part, the Ramulus Cinnamomi of 3-10 part and the Radix Salviae Miltiorrhizae of 8-15 part.
Above-mentioned Herba Dianthi, the Radix Clematidis of 7-10 part, the Radix Gentianae Macrophyllae of 6-12 part, the Ramulus Cinnamomi of 6-10 part and the Radix Salviae Miltiorrhizae of 8-12 part that is used to prevent and treat pharmaceutical composition 8-13 part of gouty arthritis and hyperuricemia.
The above-mentioned dosage form that is used to prevent and treat the pharmaceutical composition of gouty arthritis and hyperuricemia is tablet, pill, dissolved granule, capsule, soft capsule or liquid preparation.
Advantage of the present invention is:
The pharmaceutical composition that is used to prevent and treat gouty arthritis and hyperuricemia provided by the present invention has the kidney tonifying diuretic, and the effect of liver-smoothing, qi-regulating reaches the effect that strengthens patient's metabolic function, cures gout from the source.Prove that through clinical use medicine of the present invention can reduce patient with gout blood uric acid content, alleviating pain suppresses uric acid and increases, have no side effect, and this pharmaceutical composition UR treatment large contingent, satisfactory for result.
The specific embodiment
The invention provides a kind of pharmaceutical composition that is used to prevent and treat gouty arthritis and hyperuricemia, in medicament composing prescription of the present invention, is principal agent with Radix Clematidis, Radix Gentianae Macrophyllae, Herba Dianthi:
Radix Clematidis can wind-damp dispelling, again can the meridian dredging and pain relieving is dispelling the wind and dampness pathogens arthralgia pain key medicine, and the pharmacology confirms that it has stronger anti-inflammatory analgetic effect, and blood pressure lowering, effect in reducing blood glucose are arranged;
Radix Gentianae Macrophyllae has expelling wind and removing dampness and blood Shujin, and the effect of clearing away heat and promoting diuresis also has the effect of analgesia, blood pressure lowering;
The Herba Dianthi inducing diuresis for treating stranguria syndrome, the main kidney qi of supporting.
This three is a principal agent with its treating both the principal and secondary aspects of a disease.
Ramulus Cinnamomi has the effect of promoting the flow of QI-blood by warming the meridian.Can blood vessel dilating, regulate blood circulation, playing analgesic activity is accessory drugs.
Radix Salviae Miltiorrhizae has coronary artery dilator, improves myocardial ischemia, infraction and cardiac function, regulates the rhythm of the heart; Microcirculation improvement improves body's hypoxia tolerance, blood fat reducing; Nervus centralis is had calmness and analgesic activity, and can effectively improve renal function, the enhancing liver function is an adjuvant drug.
All medicine compatibilities are unique, share science.
Can compositions of the present invention be processed any dosage form that is suitable for clinically, for example pill, tablet, capsule, granule, oral liquid etc. through the conventional method for preparing of this area.
For example can the raw material water in the above-mentioned prescription be decocted one or many, collecting decoction filters, and is condensed into fluid extract, and drying is pulverized, and granulates, and incapsulates, and processes capsule preparations.
The present invention can also decoct one or many with the raw material water in the above-mentioned prescription, and collecting decoction filters, and processes oral liquid.
The invention provides a kind of pharmaceutical composition that is used to prevent and treat gouty arthritis and hyperuricemia; Comprise the Herba Dianthi of 7-15 part, Radix Clematidis and the Radix Gentianae Macrophyllae of 5-13 part, the especially Herba Dianthi of 8-13 part, the Radix Clematidis of 7-10 part and the Radix Gentianae Macrophyllae of 6-12 part of 5-10 part.
Meanwhile, the pharmaceutical composition that is used to prevent and treat gouty arthritis and hyperuricemia provided by the present invention can also comprise the Ramulus Cinnamomi of 3-10 part, the preferably Ramulus Cinnamomi of 6-10 part; And the Radix Salviae Miltiorrhizae of 8-15 part, the preferably Radix Salviae Miltiorrhizae of 8-12 part.
The dosage form that is used to prevent and treat the pharmaceutical composition of gouty arthritis and hyperuricemia provided by the present invention can be that tablet, capsule preparations, liquid preparation or other medical science allow; The reagent type that human body is accepted; Being not limited to the present invention enumerates concentrated; Can be according to dosage form different, processing method is also slightly had any different, but the thing of essence all is the same.
The inventor obtains following proportioning embodiment through long-term practice, and this proportioning embodiment can reach beneficial effect of the present invention.
Utilize different proportioning embodiment provided by the present invention, according to following method, carried out the test of many groups specific aim, its concrete Therapeutic Method is:
Raw material water provided by the present invention is decocted one or many, and collecting decoction is processed packed decoction, and two bags every dose, every bag of 200ml, one day twice, each one bag.12 days is a course of treatment, generally once takes a course of treatment.
Treatment for the first time: 12 days is a course of treatment, and every day, twice heating garment used decoction sooner or later.
Treatment for the second time: for treatment for the first time finishes back 1 year, take 12 days 1 courses of treatment again, to promote curative effect.
Treatment for the third time: for treating back 2 years for the second time, take a course of treatment again, reach the effect of consolidating effect.
After being interrupted treatment 1-3 time, observing time 1 year to triennium, 96.3% patient is under the normal situation of diet, no longer morbidity, and hematuria acid number recovers normally.
Observation of curative effect:
Criterion of therapeutical effect: with reference to " traditional Chinese medical science disease diagnosis criterion of therapeutical effect ".
Recovery from illness: transference cure, the blood uric acid inspection is normal.
Take a turn for the better: arthroncus is subdued, pain relief, and lab testing has and improves (blood uric acid descends and surpasses 30%).
Invalid: symptom and lab testing no change (blood uric acid descends and is no more than 30%).
Therapeutic outcome: all treat 1 course of treatment for two groups.
Embodiment one:
Choose prescription and get medicine-feeding with being decocted in water for oral dose every day 2 times, 12 days courses of treatment for 10 parts for 7 parts of Herba Dianthis, 8 parts of Radix Clematidis, Radix Gentianae Macrophyllae; Through in the past few years clinical 153 routine patients are treated, wherein carry out 15 examples of seance, carry out 132 examples of two treatments; Carry out 6 examples of three treatments, 122 examples of fully recovering, cure rate 79.7%; Produce effects 21 examples, obvious effective rate 13.5%, total effective rate 93.46%.
Embodiment two:
Choose prescription and get medicine-feeding with being decocted in water for oral dose every day 2 times, 12 days courses of treatment for 6 parts for 15 parts of Herba Dianthis, 6 parts of Radix Clematidis, Radix Gentianae Macrophyllae; Through in the past few years clinical 78 routine patients being treated, wherein carry out 4 examples of seance, carry out 74 examples of two treatments; 67 examples of fully recovering, cure rate 85.9%, produce effects 8 examples; Obvious effective rate 10.2%, total effective rate 96.1%.
Embodiment three:
Choose prescription and get medicine-feeding with being decocted in water for oral dose every day 2 times, 12 days courses of treatment for 12 parts for 15 parts of Herba Dianthis, 8 parts of Radix Clematidis, 5 parts of Radix Gentianae Macrophyllae, 3 parts of Ramulus Cinnamomi and Radix Salviae Miltiorrhizae; Through in the past few years clinical 200 routine patients being treated, wherein carry out 9 examples of seance, carry out 165 examples of two treatments; Carry out 28 examples of three treatments, 174 examples of fully recovering, cure rate 87.0%; Produce effects 22 examples, obvious effective rate 11%, total effective rate 98%.
Embodiment four:
Choose prescription and get medicine-feeding with being decocted in water for oral dose every day 2 times, 12 days courses of treatment for 11 parts for 10 parts of Herba Dianthis, 10 parts of Radix Clematidis, 7 parts of Radix Gentianae Macrophyllae, 10 parts of Ramulus Cinnamomi and Radix Salviae Miltiorrhizae; To clinical 164 routine patient treatments, wherein carry out 6 examples of seance through in the past few years, carry out 132 examples of two treatments; Carry out 26 examples of three treatments, 133 examples of fully recovering, 81.2%; Produce effects 25 examples, 15.1%, total effective rate 96.3%.
Claims (7)
1. pharmaceutical composition that is used to prevent and treat gouty arthritis and hyperuricemia is characterized in that: the pharmaceutical composition that is used to prevent and treat gouty arthritis and hyperuricemia comprises the Herba Dianthi of 7-15 part, the Radix Clematidis of 5-10 part and the Radix Gentianae Macrophyllae of 5-13 part.
2. the pharmaceutical composition that is used to prevent and treat gouty arthritis and hyperuricemia according to claim 1 is characterized in that: the said pharmaceutical composition that is used to prevent and treat gouty arthritis and hyperuricemia comprises the Herba Dianthi of 8-13 part, the Radix Clematidis of 7-10 part and the Radix Gentianae Macrophyllae of 6-12 part.
3. the pharmaceutical composition that is used to prevent and treat gouty arthritis and hyperuricemia according to claim 1 is characterized in that: the said pharmaceutical composition that is used to prevent and treat gouty arthritis and hyperuricemia comprises the Herba Dianthi of 7-15 part, the Radix Clematidis of 5-10 part, the Radix Gentianae Macrophyllae of 5-13 part and the Ramulus Cinnamomi of 3-10 part.
4. the pharmaceutical composition that is used to prevent and treat gouty arthritis and hyperuricemia according to claim 3 is characterized in that: the said pharmaceutical composition that is used to prevent and treat gouty arthritis and hyperuricemia comprises the Herba Dianthi of 8-13 part, the Radix Clematidis of 7-10 part, the Radix Gentianae Macrophyllae of 6-12 part and the Ramulus Cinnamomi of 6-10 part.
5. the pharmaceutical composition that is used to prevent and treat gouty arthritis and hyperuricemia according to claim 3 is characterized in that: the said pharmaceutical composition that is used to prevent and treat gouty arthritis and hyperuricemia comprises the Herba Dianthi of 7-15 part, the Radix Clematidis of 5-10 part, the Radix Gentianae Macrophyllae of 5-13 part, the Ramulus Cinnamomi of 3-10 part and the Radix Salviae Miltiorrhizae of 8-15 part.
6. the pharmaceutical composition that is used to prevent and treat gouty arthritis and hyperuricemia according to claim 5 is characterized in that: said Herba Dianthi, the Radix Clematidis of 7-10 part, the Radix Gentianae Macrophyllae of 6-12 part, the Ramulus Cinnamomi of 6-10 part and the Radix Salviae Miltiorrhizae of 8-12 part that is used to prevent and treat pharmaceutical composition 8-13 part of gouty arthritis and hyperuricemia.
7. according to the described pharmaceutical composition that is used to prevent and treat gouty arthritis and hyperuricemia of the arbitrary claim of claim 1 to 6, it is characterized in that: the said dosage form that is used to prevent and treat the pharmaceutical composition of gouty arthritis and hyperuricemia is tablet, pill, dissolved granule, capsule, soft capsule prepn or liquid preparation.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 201010214332 CN102309561B (en) | 2010-06-30 | 2010-06-30 | Pharmaceutical composition used for preventing and treating urarthritis and hyperuricemia |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 201010214332 CN102309561B (en) | 2010-06-30 | 2010-06-30 | Pharmaceutical composition used for preventing and treating urarthritis and hyperuricemia |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102309561A true CN102309561A (en) | 2012-01-11 |
| CN102309561B CN102309561B (en) | 2013-05-01 |
Family
ID=45423370
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 201010214332 Expired - Fee Related CN102309561B (en) | 2010-06-30 | 2010-06-30 | Pharmaceutical composition used for preventing and treating urarthritis and hyperuricemia |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102309561B (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106139009A (en) * | 2016-08-03 | 2016-11-23 | 韩洁茹 | A kind of Chinese medicine composition purposes in the medicine of preparation treatment chronic gout |
| CN108619427A (en) * | 2018-05-25 | 2018-10-09 | 孙益 | A kind of pain deacidification medicinal herb tea of dispelling of prophylactic treatment urarthritis |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1720943A (en) * | 2005-06-03 | 2006-01-18 | 上海中医药大学附属曙光医院 | A kind of medicinal composition for the treatment of hyperuricemia and urate nephropathy |
-
2010
- 2010-06-30 CN CN 201010214332 patent/CN102309561B/en not_active Expired - Fee Related
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1720943A (en) * | 2005-06-03 | 2006-01-18 | 上海中医药大学附属曙光医院 | A kind of medicinal composition for the treatment of hyperuricemia and urate nephropathy |
Non-Patent Citations (2)
| Title |
|---|
| 《中医药学刊》 20040228 郭峰，钱先 《痛风性关节炎的中医药治疗研究辑要》 第275-276页 1-7 第22卷, 第2期 * |
| 《基层医学论坛》 20090315 蒋连庆 《中西医结合治疗痛风65 例临床观察》 第236-237页 1-7 第13卷, 第5期 * |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106139009A (en) * | 2016-08-03 | 2016-11-23 | 韩洁茹 | A kind of Chinese medicine composition purposes in the medicine of preparation treatment chronic gout |
| CN106139009B (en) * | 2016-08-03 | 2018-05-29 | 黑龙江中医药大学 | A kind of purposes of Chinese traditional medicine composition in the drug for preparing treatment chronic gout |
| CN108619427A (en) * | 2018-05-25 | 2018-10-09 | 孙益 | A kind of pain deacidification medicinal herb tea of dispelling of prophylactic treatment urarthritis |
| CN108619427B (en) * | 2018-05-25 | 2020-11-13 | 孙益 | Pain-relieving and acid-reducing herb tea for preventing and treating gouty arthritis |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102309561B (en) | 2013-05-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101032580B (en) | Medicine for treating rheumatic diseases | |
| CN103202879B (en) | Traditional Chinese medicine composition for treating chronic cardiac failure and preparation method thereof | |
| CN104758806A (en) | Decocted extract for treating coronary heart disease and preparation method thereof | |
| CN102631538B (en) | Traditional Chinese medicine for treating heart disease | |
| CN102309561B (en) | Pharmaceutical composition used for preventing and treating urarthritis and hyperuricemia | |
| CN101085233A (en) | Civil Chinese medicinal herb with hypotensive, antilipemic and hypoylycemic function | |
| CN102343049B (en) | Chinese medicinal capsules for treating hypertension due to liver-yang hyperactivity | |
| CN104524342A (en) | Traditional Chinese medicine preparation for lowering high blood pressure, high blood sugar, high cholesterol, high uric acid and maintaining vigor and preparation method of plaster of traditional Chinese medicine preparation | |
| CN101214314A (en) | Chinese medicine for treating cerebral apoplexy | |
| CN104147346A (en) | Traditional Chinese medicinal compound for treating coronary diffuse lesion angina | |
| CN103055122B (en) | The medicine and preparation method thereof of restenosis after prevention percutaneous transluminal coronary stent implantation | |
| CN102579688B (en) | Blood pressure reducing chrysanthemum and dogbane leaf traditional Chinese medicine preparation | |
| CN106109951A (en) | Prevent and treat medicine of hyperglycemia, hyperlipidemia, hypertension and preparation method thereof | |
| CN102552715B (en) | Chinese medicinal composition, medicine containing Chinese medicinal composition and preparation method of medicine | |
| CN102274357B (en) | Pharmaceutical composition for treating coronary arteriosclerotic heart disease and preparation method thereof | |
| CN105126034A (en) | Pharmaceutical preparation for treating coronary heart disease | |
| CN101417075B (en) | Traditional Chinese medicine for treating respiratory system disease | |
| CN105435196A (en) | Externally-applied traditional Chinese medicine ointment for treating qi stagnation and blood stasis coronary angina pectoris with chronic gastritis and preparation method thereof | |
| CN103948767A (en) | Pharmaceutical composition for treating cardiovascular and cerebrovascular diseases, as well as preparation method and application thereof | |
| CN108096536A (en) | A kind of Chinese medicine composition for treating hemiplegia | |
| CN103768454A (en) | Composition for preventing and treating HIV/AIDS (Human Immunodeficiency Virus/ Acquired Immune Deficiency Syndrome) and preparation method thereof | |
| CN103961603B (en) | Traditional Chinese medicine preparationcapable of reducing blood fat and freeing vessels | |
| CN101244209B (en) | Medicament for preventing or treating cardiovascular and cerebrovascular diseases | |
| CN105343358A (en) | Traditional Chinese medicine capsules for treating coronary heart disease | |
| CN101088534B (en) | Medicine composition for treating bone necrosis and its preparation process |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C41 | Transfer of patent application or patent right or utility model | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20161111 Address after: On the west side of the East Cang Xiang, Beilin District 710001 in Shaanxi city of Xi'an province No. 3 News Agency Patentee after: Zhang Ke Address before: Ming Park District 710016 in Shaanxi province Xi'an City Weiyang District Xuanwu Road 2 Room No. 1202 provincial organs Patentee before: Xi'an Shanyuan Gout Institute of Chinese Medicine |
|
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20130501 Termination date: 20200630 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |